THE SHIELD AGAINST PROGRESSION IN mCRPC

Enhance your ability to fight BRCA-mutated mCRPC at its core with RUBRACA

RUBRACA is the ONLY PARPi that can be used as a monotherapy following ANY androgen receptor-directed therapy and a taxane-based chemotherapy1-4*

RUBRACA challenges the current PARP inhibitor (PARPi) standard of care by providing a flexible, targeted, effective, and supportive treatment for patients with BRCA-mutated mCRPC

Doctor using a shield made of light.
Person inside hexagon with three circles around it.

Flexible

The ONLY PARPi that can be used as a monotherapy following ANY androgen receptor-directed therapy and a taxane-based chemotherapy1-4*
DNA strand with a circle in the middle.

Targeted

Specifically treats BRCA-mutated mCRPC patients1
Bar chart with a downward arrow.

Effective

Demonstrated clinically meaningful results5

Three people in a circle.

Supportive

Offers comprehensive support for your patients and access support for your practice

*Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

Demonstrated improvements in multiple efficacy outcomes: confirmed ORR by IRR, 46% (95% CI, 35%-57%); median DOR by IRR, 15.5 months (95% CI, 6.4-not reached).

BRCA, BReast CAncer gene; DOR, duration of response; IRR, independent radiology review; mCRPC, metastatic castration-resistant prostate cancer; ORR, objective response rate; PARPi, poly (adenosine diphosphate-ribose) polymerase inhibitor.

REFERENCES: 1. RUBRACA (rucaparib). Prescribing Information. pharma& Schweiz GmbH. 2023. 2. Lynparza (olaparib). Prescribing Information. AstraZeneca Pharmaceuticals LP. 2023. 3. Akeega (niraparib and abiraterone acetate). Prescribing Information. Janssen Biotech, Inc. 2023. 4. Talzenna (talazoparib). Prescribing Information. Pfizer Inc. 2024. 5. Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol. 2023;84:321-330. 6. Tawagi K, Schmolze M, Nguyen B, Laviana A, Reizine N. PARP inhibitors in prostate cancer – understanding the current landscape. IJCCD. 2024;4(1).

RUBRACA PATIENT WEBSITE
COMING SOON! 

RUBRACA PATIENT
WEBSITE COMING SOON! 

The information contained in this website is intended for US healthcare professionals only.

By clicking the button below, you acknowledge that you are a US healthcare professional.

YOU ARE NOW LEAVING RubracaProstateHCP.com

Are you sure you want to leave?

Skip to content